Early systemic sclerosis-opportunities for treatment.

Area of Science:

• Rheumatology
• Immunology
• Dermatology

Background:

• Systemic sclerosis (SSc) involves microvasculopathy, autoantibodies, and fibrosis in skin and organs.
• Early SSc markers like microvasculopathy and autoantibodies often precede visible scleroderma and organ damage.
• Current diagnosis relies on scleroderma, by which time potentially lethal organ fibrosis may be advanced.

Purpose of the Study:

• To highlight the significance of early Systemic Sclerosis (SSc) detection.
• To emphasize the role of new classification criteria in identifying SSc before irreversible organ fibrosis.
• To advocate for early immunosuppressive treatment in SSc.

Main Methods:

• Review of SSc pathogenesis, diagnostic markers, and classification criteria.
• Focus on microvasculopathy (nailfold capillaroscopy) and autoantibodies (anti-topoisomerase I, anti-centromere, anti-RNA polymerase III).
• Discussion of the 2013 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria.

Main Results:

• Microvasculopathy and autoantibodies are early indicators of SSc, appearing years before skin manifestations.
• The 2013 EULAR/ACR criteria aid in identifying SSc patients at an earlier, pre-fibrotic stage.
• Early diagnosis facilitates the controlled introduction of immunosuppressive therapies.

Conclusions:

• Early identification of SSc is crucial to prevent or mitigate organ fibrosis.
• Implementing new classification criteria can lead to earlier diagnosis and intervention.
• Timely immunosuppressive treatment holds promise for improving the prognosis of Systemic Sclerosis.